SCHEMBL29655102

SCHEMBL29655102

Nc1cccc(F)c1-c1cc(F)cc([N+](=O)[O-])c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ CYP19A1 P11511 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ LMNA P02545 3/20 0.38
▸ TSHR P16473 1/20 0.38
▸ F7 P08709 1/20 0.37
▸ F3 P13726 1/20 0.37
▸ MGAM O43451 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ SI P14410 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ MGAM2 Q2M2H8 1/20 0.37
▸ TDP1 Q9NUW8 3/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29655051 0.87 ALDH1A1 (0.46) ALDH1A1CYP19A1NPC1RAB9ALMNA
SCHEMBL27710643 0.75 TSHR (0.45) PGRALDH1A1NPC1RAB9ALMNA
SCHEMBL29655097 0.75 ALDH1A1 (0.47) ALDH1A1NPC1RAB9ALMNATSHR
SCHEMBL15570821 0.73 CYP19A1 (0.54) PGRALDH1A1CYP19A1NPC1RAB9A
SCHEMBL11899912 0.71 TDP1 (0.66) ALDH1A1LMNATSHRF7F3
SCHEMBL27710597 0.70 CA2 (0.40) PGRALDH1A1NPC1TDP1MEN1
SCHEMBL2935984 0.70 P2RX1 (0.43) ALDH1A1LMNATSHRGAAMAPT
SCHEMBL13917956 0.69 TSHR (0.57) PGRALDH1A1CYP19A1NPC1RAB9A
SCHEMBL6649940 0.69 LMNA (0.54) PGRALDH1A1NPC1RAB9ALMNA
SCHEMBL1172437 0.69 CYP19A1 (0.55) PGRALDH1A1CYP19A1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109843874-B Phthalazine derivatives useful as inhibitors of PARP1, PARP2 and/or tubulin for the treatment of cancer 加利福尼亚大学董事会 2022-05-27 — — CN disclosed
Send feedback